FDA declines to approve Summit's lung cancer drug ivonescimab over lack of survival benefit

The U.S. Food and Drug Administration (FDA) has declined to approve ivonescimab, a lung cancer drug developed by Summit Therapeutics. STAT News and Reuters both report the decision, which was made public on Sunday, 15 November 2026.

Both outlets link the rejection to the drug not showing a survival benefit. STAT News reports that the drug did not help patients live longer. Reuters reports that the trial missed a key survival goal.

Background

According to STAT News, Summit developed ivonescimab together with the Chinese drugmaker Akeso. Summit oversees development of the drug outside China, STAT News reports. Summit announced the rejection, according to the same outlet.

STAT News reports that the drug was found to slow the worsening of lung cancer in patients. According to Reuters, the drug was intended for patients whose cancer has progressed after earlier therapies.

According to STAT News, FDA regulators sent a letter to the companies. The letter stated that the drug could not be approved because it did not help patients live longer, STAT News reports.

What each side says

FDA reviewers: According to STAT News, which cites the letter sent to the companies, the reviewers said that without a survival benefit, the drug's benefit-risk profile does not support approval. STAT News quoted the letter as saying the data "does not support the positive benefit-risk profile in support of approval."

Summit Therapeutics: According to STAT News, Summit announced that the FDA had rejected ivonescimab. The reports reviewed by Vocemundi do not include any further comment from Summit or Akeso. They do not describe the companies' next steps, such as resubmitting the application, running further trials or appealing.

What the reports do not include

The reports do not identify the clinical trial or trials behind the application. They do not give survival or progression figures. They do not state the specific type or stage of lung cancer. STAT News refers to "a type of lung cancer".

The reports do not include any direct statement from the FDA. The letter's contents are known only as STAT News describes them. The reports also do not say whether the decision affects the drug's status in China or other markets.

STAT News and Reuters report independently. However, STAT News attributes the news to Summit's own announcement, and Reuters does not name its source. Both reports may therefore trace back to the company's disclosure. Vocemundi did not review either full article: only an excerpt of the STAT News report, which is labelled "STAT+", and a short Reuters summary were available.

Analysis

The decision, as reported, highlights the weight regulators can place on overall survival when weighing a drug's benefits and risks. A slowing of disease progression alone was not enough in this case, according to STAT News. Several paths are possible. The companies could seek further data, revise the application or pursue other options, but the reports do not describe their plans. The effect on the drug outside the United States, including in China, is not addressed in the reports. Without trial figures or a full FDA statement, readers cannot yet assess how close the drug came to meeting the survival goal.

Produced by the Vocemundi newsroom with AI assistance.